Risk-benefit of OKT3 prophylaxis in immunologic high-risk cadaver kidney transplant recipients

Transplant Proc. 1997 Nov;29(7A):32S-34S. doi: 10.1016/s0041-1345(97)80009-7.
No abstract available

MeSH terms

  • Cadaver
  • Cost-Benefit Analysis
  • Hospitalization / economics
  • Humans
  • Immunosuppression Therapy / economics
  • Immunosuppressive Agents / economics
  • Kidney Diseases / therapy*
  • Kidney Transplantation / immunology*
  • Muromonab-CD3 / economics*
  • Muromonab-CD3 / therapeutic use
  • Peritoneal Dialysis / economics
  • Survival Analysis

Substances

  • Immunosuppressive Agents
  • Muromonab-CD3